NOVT
Get informed when a big investor buys or sells
+ FollowOvervalued by 78.5% based on the discounted cash flow analysis.
| Market cap | $5.53 Billion |
|---|---|
| Enterprise Value | $5.43 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.47 |
| Beta | 1.68 |
| Outstanding Shares | 40,425,000 |
| P/E Ratio | 116.87 |
|---|---|
| PEG | -22738.34 |
| Price to Sales | 6.31 |
| Price to Book Ratio | 4.73 |
| Enterprise Value to Revenue | 5.41 |
| Enterprise Value to EBIT | 48.58 |
| Enterprise Value to Net Income | 101 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.22 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.9945▼ 432.40% |
|---|---|
| Total Calls | 109,300▲ 709.63% |
| Total Puts | 436,600▲ 288.78% |
Holdings and activity of institutional investors.
| Ownership % | 110.69%▲ 2.14% |
|---|---|
| Total Invested | $4.78B▲ 3.64% |
| Investors Holding | 341▲ 8.00% |
No data
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers ('OEMs') a competitive advantage. Novanta combines deep proprietary technology expertise and com...
This committee provides the official revenue estimates and technical analysis for all tax bills, directly influencing corporate tax structures, capital investment credits, and the overall tax burden on industries like manufacturing, critically impacting Novanta's financial outlook.
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy, tariffs, and Medicare pricing can directly impact Novanta's profitability, global supply chain, and demand from its medical OEM customers.
This committee directly allocates discretionary federal spending, determining the precise cash flow for defense programs, scientific research, and infrastructure projects that could utilize Novanta's components and directly impact its potential order books.
This committee directly impacts Novanta's medical OEM customers through FDA regulations on medical devices and influences medical R&D via NIH. Its oversight of labor laws also directly affects Novanta's manufacturing costs.
Novanta's precision motion, photonics, and vision technologies are highly relevant to defense applications and emerging military technologies, making this committee's funding authorizations directly impactful on potential demand from defense contractors.
This committee has broad oversight over interstate commerce, science, and industries like aerospace and telecommunications, which are key markets for Novanta's precision motion, vision, and photonics technologies. It also influences R&D.